Navigation Links
Delpor Awarded $220K NIH Grant for 3-month Exenatide Implant for the Treatment of Type 2 Diabetes
Date:10/17/2014

SAN FRANCISCO, CA (PRWEB) October 17, 2014

Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced the awarding of a $222K grant (Grant number: 1R43DK101257-01A1) from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for the further advancement of the company’s 3-month exenatide product (DLP-414). The product is based on Delpor’s NANOPOR technology and is expected to deliver therapeutic levels of exenatide for a period of at least 3 months.

"We are very excited to receive this grant award and extremely grateful to the NIDDK for helping us advance our research in developing a unique product, which could offer substantial benefits to patients with type 2 diabetes." said Tassos Nicolaou, President and CEO of Delpor. "We plan to employ these new funds to build on current macromolecular stabilization data and test a variety of nanopore membranes in-vivo.”

Approximately 10% of U.S. adults have diabetes and the Centers for Disease Control and Prevention project as many as 1 in 3 U.S. adults could have diabetes by 2050. Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. The short plasma half-life of GLP-1 peptides presents a delivery challenge. As a result, developing extended duration delivery options will result in significant advances related to patient medication adherence and convenience.

Tassos Nicolaou continued: “The current exenatide therapy consists of daily or weekly injections. Such injections can be invasive and often result in non-adherence to therapy. DLP-414 has the potential to extend the exenatide formulation for as long as one year, while offering full reversibility in case the patient has a treatment related adverse event.” Mr. Nicolaou concluded by saying: “Our nanopore technology has already been validated, and shown to release several proteins and peptides with near zero-order kinetics in vitro and in vivo. What is unique about Delpor’s technology is the ability to achieve such kinetics through passive diffusion. Our implant device is non-mechanical and does not include any moving parts. This simplifies the design and allows us to make the implant even smaller for drugs that are potent enough.”

About Delpor, Inc.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company’s technologies enable the sustained release of drugs through a small non-mechanical subcutaneous implant device. The device is implanted during a 10 minute, simple, in-office, procedure using local anesthetic and without the need for any surgical sutures. Delpor’s device can deliver small & large molecules within a predefined therapeutic window over several months while maintaining zero-order release pharmacokinetics. Delpor is focusing on the delivery of biologics and antipsychotics in order to improve medication adherence, safety and convenience. The company’s lead products include 3-6 month formulations of Exenatide and Risperidone. Additional information about the company can be found at http://www.delpor.com.

About DLP-414
Delpor’s DLP-414 is a small titanium reservoir designed for subcutaneous implantation and loaded with a unique formulation of exenatide. The product is designed to provide a constant therapeutic dose of exenatide each day for a total period of 3-12 months. Additional features include reversibility, immediate onset of action, and no accumulation.

Forward-Looking Statements
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Contacts
Delpor, Inc.
Tassos Nicolaou, President and CEO
Phone: 415-480-6873
Fax:     415-480-6871

Read the full story at http://www.prweb.com/releases/2014/10/prweb12247910.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Delpor Awarded $340K NIH Grant for 3-month Long Acting Risperidone Product in order to Improve Medication Adherence in Schizophrenia and Bipolar Disorder
2. TomoWave Laboratories, Inc., Houston, Texas is pleased to announce that Dr. Alexander Oraevsky has been awarded the First Place Innovations Prize from Berthold Leibinger Foundation for invention and development of the laser optoacoustic imaging syst
3. Shuji Nakamura, a Scientific Adviser of Seoul Semiconductor and Seoul Viosys, Was Awarded the Nobel Prize in Physics 2014
4. $100,000 Awarded to e-Chromic Technologies and PAX Pure for their Clean Tech Business Solutions
5. Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics
6. Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA)
7. Synedgen Awarded National Cancer Institute Funding for Promising New Treatment for Medical Radiation-induced Bowel Injury
8. Scripps Research Institute scientists awarded $7.9 million to develop artificial immune system
9. BellBrook Labs and UW-Madison Team Awarded NCI Contract to Develop Next Generation Cancer Models
10. GenoSpace Awarded Fast Track SBIR Grant to Enable Data Access and Cohort Construction for Biorepositories
11. Western IRB (WIRB) Awarded AAHRPP Reaccreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... RPS ... clinical study that demonstrates the accuracy of the FebriDx® test, a commercially-ready, ... acute bacterial and viral respiratory tract infections by testing the body’s immune ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, a global ... industries to improve patient outcomes and quality of life, will now be offering ... being attributed to new regulatory requirements for all new drug products, including the ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, CEO ... ASTER Labs ), Inc. has been selected for membership in ARCS Alumni ...
(Date:10/11/2017)... ... , ... Personal eye wash is a basic first aid supply for any work environment, but ... do you rinse first if a dangerous substance enters both eyes? It’s one less decision, ... its unique dual eye piece. , “Whether its dirt and debris, or an acid or ...
Breaking Biology Technology:
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University ... adopting ground breaking 3D fingerprint minutiae recovery and matching technology, pushing ... for use in identification, crime investigation, immigration control, security of access ... ... A research team led by Dr Ajay ...
Breaking Biology News(10 mins):